Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Myelodysplastic Syndromes 6Lymphoma 4Hematologic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 3Leukemia, Myeloid, Acute 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia 3Neoplasm, Residual 2Lymphoma, Non-Hodgkin 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Osteosarcoma 1Neurotoxicity Syndromes 1Neuroblastoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Lymphohistiocytosis, Hemophagocytic 1Lymphatic Diseases 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Immunoproliferative Disorders 1Immune System Diseases 1

Interventions

Fluorouracil 71pembrolizumab 62Bevacizumab 60Oxaliplatin 59Cetuximab 59Leucovorin 56Irinotecan 55Capecitabine 31Nivolumab 23Gemcitabine 18Cisplatin 18IFL protocol 17Folfox protocol 17Cyclophosphamide 16Carboplatin 15atezolizumab 14Specimen Handling 14Paclitaxel 14Magnetic Resonance Spectroscopy 14Biopsy 14trifluridine tipiracil drug combination 12Pemetrexed 10spartalizumab 9regorafenib 9fludarabine 9Panitumumab 9130-nm albumin-bound paclitaxel 9trametinib 8durvalumab 8dehydroftorafur 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Colorectal Neoplasms × AP 1903 reagent × Clear all
NCT06358430 2026-05-20

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

M.D. Anderson Cancer Center

Phase 1 Recruiting
42 enrolled
Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡